Business Services Industry

Advanced Viral Research Corp. Announces Private Placement

Business Wire, Oct 17, 1997

YONKERS, N.Y.--(BUSINESS WIRE)--Oct. 14, 1997--Advanced Viral Research Corp. (NASDAQ BB:ADVR) of Yonkers, Tuesday announced a private placement of a 7% ten year convertible debenture to a European financial institution.

The debenture is convertible into common stock at 70% of the average closing prices for the five consecutive trading days before the conversion date. In addition, the company issued warrants to purchase an aggregate of 1,800,000 common shares at a price ranging from $.20 to $.27 per share pursuant to Regulation S of the Securities Act of 1933.

The financing, in the amount of $3 million (gross), will be used to help fund the company's ongoing research and development program for its drug RETICULOSE, as well as the appointment of qualified scientists and initiating the formal process for seeking governmental approvals to market RETICULOSE.

Advanced Viral Research Corp. is a biotechnology company specializing in the new pharmacology of peptide nucleic acids. RETICULOSE, the company's peptide nucleic acid preparation, is a non-toxic, broad spectrum anti-viral drug, currently under clinical study for the treatment of AIDS.

CONTACT: Advanced Viral Research Corp.

Phone: 954/458-7636 Fax: 954/458-4715

COPYRIGHT 1997 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Thompson Gale